In October 2025, Japan's Pharmaceutical & Food Safety Bureau's Pharmaceutical Affairs Council formally ruled that CBN (cannabinol) designation as a specified drug under the Cannabis Control Act was "appropriate." A ministerial notice promulgating the designation was widely expected in February 2026. That notice has not been issued.
Bottom line: The February deferral does not mean CBN has been cleared. The designation intent has not changed. Continue treating CBN as effectively prohibited for import purposes until further notice.
What a "Deferral" Actually Means in Japanese Administrative Law
In Japan's pharmaceutical regulatory process, a council ruling that designation is "appropriate" is a formal administrative step — but it is not the designation itself. The actual legal effect comes from a ministerial notice (省令) promulgated by the Minister of Health, Labour and Welfare. Until that notice is published in the Official Gazette, CBN is not technically a designated substance.
The February 2026 deferral appears to have resulted from two factors: review of public comments submitted during the consultation period, and ongoing consideration of a special pathway for existing medical use cases. Neither factor signals any change in the substantive outcome.
Why This Deferral Does Not Help You
Several international brands have interpreted the deferral as an opportunity — a window to continue importing CBN products until formal designation. This interpretation is operationally dangerous for several reasons:
- Customs pre-clearance risk: Japan Customs has been briefed on the pending designation. Products containing CBN face heightened scrutiny and potential hold regardless of formal legal status.
- MHLW import notification: The Ministry is unlikely to process new import notifications for products containing CBN at this stage of the designation process.
- Retailer risk exposure: Domestic retailers are already declining to accept CBN products. A supply chain built on a product that cannot reach shelves has no commercial value.
- Inventory stranding: Stock that arrives in Japan during the deferral window may be stranded if designation is promulgated before it clears customs or sells through.
Timeline: How We Got Here
Understanding the full timeline helps clarify why the current position is as firm as it is:
- May 2025: A Yamanashi prefectural university student fell from a building after reportedly consuming a high-dose CBN cookie purchased online. The incident triggered formal MHLW investigation.
- July 2025: MHLW commissioned psychotoxicity studies on CBN. Results were submitted to the Pharmaceutical Affairs Council.
- October 2025: The Council ruled designation "appropriate" following review of the toxicity data and international regulatory precedents.
- November–January: Public comment period. Several industry submissions requested a medical exemption pathway and a transition period for existing inventory.
- February 2026: Expected promulgation deferred. No revised date announced.
- March 2026: MHLW has confirmed designation intent has not changed.
What CBN-Dependent Brands Should Do Now
If your product line contains CBN — including products where CBN is a secondary or trace component — the following steps are relevant regardless of when formal designation occurs:
1. Audit your full product portfolio for CBN presence
Broad-spectrum CBD extracts frequently contain measurable CBN as a natural degradation product of THC. Even products not marketed as CBN products may contain detectable levels. Re-test all products intended for Japan using a Japan-accredited laboratory with sub-0.1 ppm detection capability for CBN.
2. Evaluate reformulation pathways
For products where CBN presence is incidental rather than intentional, reformulation to isolate-based or CBN-free broad-spectrum extracts is straightforward. For products marketed specifically on CBN content, the Japanese market will require a different product format. CBG is the primary candidate replacement — currently unscheduled, commercially available, and showing strong domestic demand growth.
3. Do not submit MHLW import notifications for CBN products
Submitting import notifications for products that are in the process of being designated creates a compliance record that may complicate future applications. Wait for designation to be formally promulgated or rescinded before filing.
Practical note: If you need a formal written assessment of your specific product's status — including how CBN presence at various concentration levels is likely to be treated by Japanese authorities — Import Verdict™ can provide that documentation directly from customs and MHLW.
The CBG Opportunity
Japan's CBN market was estimated at approximately ¥10 billion in FY2024. That demand does not disappear with CBN's exit — it migrates to the next viable cannabinoid. CBG (cannabigerol) is currently unscheduled in Japan, is not under active MHLW review, and is showing rapidly increasing inquiry volume from domestic wholesale buyers. For brands positioned to enter with a compliant CBG product, the window is now.